Altimmune, Inc. (ALT): Operating Cash Flow
-$67.53M
Year ended 2025-12-31
-$76.51M
Trailing 12 months to 2026-06-30
| Period ended | Operating Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$67.53M | n/m | 2026-03-06, From 2025-01-01 |
| 2024-12-31 | -$79.85M | n/m | 2026-03-06, From 2024-01-01 |
| 2023-12-31 | -$75.81M | n/m | 2025-02-27, From 2023-01-01 |
| 2022-12-31 | -$62.59M | n/m | 2024-03-27, From 2022-01-01 |
| 2021-12-31 | -$78.24M | n/m | 2023-02-28, From 2021-01-01 |
| 2020-12-31 | -$34.31M | n/m | 2022-03-15, From 2020-01-01 |
| 2019-12-31 | -$9.60M | n/m | 2021-02-25, From 2019-01-01 |
| 2018-12-31 | -$9.39M | n/m | 2020-03-27, From 2018-01-01 |
| 2017-12-31 | -$20.21M | n/m | 2019-04-01, From 2017-01-01 |
| 2016-12-31 | -$6.35M | n/m | 2018-04-02, From 2016-01-01 |
| 2015-12-31 | -$3.22M | n/m | 2017-03-14, From 2015-01-01 |
| 2014-12-31 | -$8.47M | n/m | 2017-03-14, From 2014-01-01 |
| 2013-12-31 | -$7.17M | n/m | 2016-03-11, From 2013-01-01 |
| 2012-12-31 | -$2.32M | n/m | 2013-03-14, From 2012-01-01 |
| 2011-12-31 | -$7.81M | n/m | 2013-03-14, From 2011-01-01 |
| 2010-12-31 | -$14.86M | n/a | 2013-03-14, From 2010-01-01 |
Operating Cash Flow at similar companies
| Company | Year ended | Operating Cash Flow | Change YoY |
|---|---|---|---|
| Altimmune, Inc. (ALT) | 2025-12-31 | -$67.53M | n/m |
| Neonc Technologies Holdings, Inc. (NTHI) | 2025-12-31 | -$20.36M | n/m |
| Lyell Immunopharma, Inc. (LYEL) | 2025-12-31 | -$150.02M | n/m |
| Lunai Bioworks Inc. (LNAI) | 2026-06-30 | -$5.29M | n/m |
| Impact Biomedical Inc. (IBO) | 2025-12-31 | -$1.89M | n/m |
| HCW Biologics Inc. (HCWB) | 2025-12-31 | -$13.39M | n/m |
| Avalo Therapeutics, Inc. (AVTX) | 2025-12-31 | -$51.46M | n/m |
| Talphera, Inc. (TLPH) | 2025-12-31 | -$11.36M | n/m |
| Connect Biopharma Holdings Ltd (CNTB) | 2025-12-31 | -$51.21M | n/m |
Compare ALT, NTHI, LYEL, LNAI side by side · Screen every company in Pharmaceutical Preparations ↗